{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:01:18Z","timestamp":1787022078157,"version":"build-2736575974"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"crossref","award":["303366\/2015-0"],"award-info":[{"award-number":["303366\/2015-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The S\u00e3o Paulo Research Foundation","award":["2015\/15402-2, 2016\/26209-1, 2017\/03708-5"],"award-info":[{"award-number":["2015\/15402-2, 2016\/26209-1, 2017\/03708-5"]}]},{"name":"The S\u00e3o Paulo Research Foundation","award":["2013\/01766-7"],"award-info":[{"award-number":["2013\/01766-7"]}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R01HL130539-01A1, 1R01HL137562-01A1, K24HL113128-06"],"award-info":[{"award-number":["1R01HL130539-01A1, 1R01HL137562-01A1, K24HL113128-06"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\n Background<\/jats:title>\n Heart Failure (HF) is the most common cause of death in Friedreich\u2019s ataxia (FRDA), an inherited mitochondrial disease. Myocardial fibrosis and myocardial hypertrophy are well-documented autopsy features among FRDA patients with HF.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To leverage the unique tissue characterization features of cardiac magnetic resonance (CMR) for characterizing myocardial remodeling in patients with genetically confirmed FRDA without HF and preserved left ventricular ejection fraction (LVEF > 55%).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Twenty-seven FRDA\u2019s patients (age 27.6 \u00b1 9.7 years, 15 women) and 10 healthy controls (32.6\u00b17.3 years, 5 women) underwent a CMR for assessment of LV function, myocardial T1, late gadolinium enhancement (LGE), extracellular volume fraction (ECV), and intracellular water-lifetime (\u03c4\n ic<\/jats:sub>\n ), a marker of cardiomyocyte size.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n As compared to controls, FRDA patients had a preserved LVEF (LVEF: 70.5\u00b17.4% vs. 63.9\u00b19.0%, P<0.058), larger LV mass index (LVMASSi: 61\u00b121.7 vs. 45\u00b14.2g\/m\n 2<\/jats:sup>\n , P<0.02), and decreased LV end-diastolic volume index (LVEDVi 53.1\u00b112.0 vs. 75.7\u00b116.1ml\/m\n 2<\/jats:sup>\n , P<0.001), compared with controls. Additionally, ECV and cardiomyocyte size (\u03c4\n ic<\/jats:sub>\n ,) were larger in FRDA patients (ECV: 0.36 \u00b10.05 vs. 0.25\u00b10.02, P<0.001; \u03c4\n ic<\/jats:sub>\n : 0.15\u00b10.08 vs. 0.06\u00b10.03 s, P = 0.02). ECV and \u03c4\n ic<\/jats:sub>\n were positively associated with LV mass-to-volume ratio (ECV: r = 0.57, P = 0.003; \u03c4\n ic<\/jats:sub>\n : r = 0.39; P = 0.05). LVMASSi and cardiomyocyte mass-index [(1\u2212ECV)\u00b7LVMASSi] declined with age at the CMR exam, independent of the age at initial diagnosis.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n LV hypertrophy and concentric LV remodeling in FRDA are associated at the tissue level with an expansion of the ECV and an increase in cardiomyocyte size. The adverse tissue remodeling assessed by ECV and \u03c4\n ic<\/jats:sub>\n is associated with more severe cardiomyopathy classification, suggesting a role for these markers in tracking disease progression.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pone.0246633","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T13:22:56Z","timestamp":1616764976000},"page":"e0246633","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pre-clinical left ventricular myocardial remodeling in patients with Friedreich\u2019s ataxia: A cardiac MRI study"],"prefix":"10.1371","volume":"16","author":[{"given":"Karen A. G.","family":"Takazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago","family":"Quinaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago D.","family":"Venancio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto R. M.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi V.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G.","family":"Neilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jerosch-Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4428-5186","authenticated-orcid":true,"given":"Ot\u00e1vio R.","family":"Coelho-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcondes C.","family":"Fran\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"pone.0246633.ref001","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJM199610173351601","article-title":"Clinical and genetic abnormalities in patients with Friedreich\u2019s ataxia","volume":"335","author":"A. Durr","year":"1996","journal-title":"N Engl J Med"},{"key":"pone.0246633.ref002","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich\u2019s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion","volume":"271","author":"V. Campuzano","year":"1996","journal-title":"Science"},{"key":"pone.0246633.ref003","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/hmg\/6.11.1771","article-title":"Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes","volume":"6","author":"V. Campuzano","year":"1997","journal-title":"Hum Mol Genet"},{"key":"pone.0246633.ref004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2011.01.010","article-title":"Friedreich\u2019s ataxia: pathology, pathogenesis, and molecular genetics","volume":"303","author":"A. H. Koeppen","year":"2011","journal-title":"J Neurol Sci"},{"key":"pone.0246633.ref005","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaneurol.2015.1855","article-title":"A 22-Year Follow-up Study of Long-term Cardiac Outcome and Predictors of Survival in Friedreich Ataxia","volume":"72","author":"F. Pousset","year":"2015","journal-title":"JAMA neurology"},{"issue":"Suppl 1","key":"pone.0246633.ref006","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/jnc.12217","article-title":"Cardiomyopathy of Friedreich ataxia","volume":"126","author":"F. Weidemann","year":"2013","journal-title":"J Neurochem"},{"key":"pone.0246633.ref007","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/ejechocard\/jer267","article-title":"Normal left ventricular ejection fraction and mass but subclinical myocardial dysfunction in patients with Friedreich\u2019s ataxia","volume":"13","author":"C. Dedobbeleer","year":"2012","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"pone.0246633.ref008","first-page":"423","article-title":"Progression of cardiopathology in Friedreich ataxia: clinico-instrumental study","volume":"35","author":"F. Casazza","year":"1990","journal-title":"Cardiologia"},{"key":"pone.0246633.ref009","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehq443","article-title":"Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome","volume":"32","author":"S. V. Raman","year":"2011","journal-title":"European heart journal"},{"key":"pone.0246633.ref010","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"F. Weidemann","year":"2009","journal-title":"Circulation"},{"key":"pone.0246633.ref011","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2012.03.076","article-title":"Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy","volume":"60","author":"G. Todiere","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"pone.0246633.ref012","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","article-title":"Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)","volume":"19","author":"D. R. Messroghli","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"pone.0246633.ref013","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/CIRCULATIONAHA.112.000438","article-title":"Quantification of cardiomyocyte hypertrophy by cardiac magnetic resonance: implications for early cardiac remodeling","volume":"128","author":"O. R. Coelho-Filho","year":"2013","journal-title":"Circulation"},{"key":"pone.0246633.ref014","doi-asserted-by":"crossref","first-page":"e000790","DOI":"10.1161\/JAHA.114.000790","article-title":"Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone","volume":"3","author":"O. R. Coelho-Filho","year":"2014","journal-title":"Journal of the American Heart Association"},{"key":"pone.0246633.ref015","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.111.059477","article-title":"The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms","volume":"125","author":"F. Weidemann","year":"2012","journal-title":"Circulation"},{"key":"pone.0246633.ref016","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jcmg.2012.09.020","article-title":"Myocardial extracellular volume fraction from T1 measurements in healthy volunteers and mice: relationship to aging and cardiac dimensions","volume":"6","author":"T. G. Neilan","year":"2013","journal-title":"JACC. Cardiovascular imaging"},{"key":"pone.0246633.ref017","article-title":"Myocardial tissue remodeling after orthotopic heart transplantation: a pilot cardiac magnetic resonance study","author":"O. R. Coelho-Filho","year":"2016","journal-title":"The international journal of cardiovascular imaging"},{"key":"pone.0246633.ref018","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000156802.15466.79","article-title":"Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale","volume":"64","author":"S. H. Subramony","year":"2005","journal-title":"Neurology"},{"key":"pone.0246633.ref019","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/CIRCULATIONAHA.104.507723","article-title":"Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy","volume":"112","author":"C. Rickers","year":"2005","journal-title":"Circulation"},{"key":"pone.0246633.ref020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/(SICI)1522-2594(199909)42:3<467::AID-MRM9>3.0.CO;2-0","article-title":"Equilibrium transcytolemmal water-exchange kinetics in skeletal muscle in vivo","volume":"42","author":"C. S. Landis","year":"1999","journal-title":"Magnetic resonance in medicine"},{"key":"pone.0246633.ref021","volume-title":"Diseases of the heart and blood vessels: nomenclature and criteria for diagnosis","author":"New York Heart Association","year":"1964","edition":"6"},{"key":"pone.0246633.ref022","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/mds.21590","article-title":"Cardiomyopathy in Friedreich\u2019s ataxia-assessment by cardiac MRI","volume":"22","author":"C. Meyer","year":"2007","journal-title":"Mov Disord"},{"key":"pone.0246633.ref023","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","article-title":"Mortality in Friedreich ataxia","volume":"307","author":"A. Y. Tsou","year":"2011","journal-title":"J Neurol Sci"},{"key":"pone.0246633.ref024","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/echo.12287","article-title":"Longitudinal strain in Friedreich Ataxia: a potential marker for early left ventricular dysfunction","volume":"31","author":"M. St John Sutton","year":"2014","journal-title":"Echocardiography"},{"key":"pone.0246633.ref025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.amjcard.2011.09.025","article-title":"Analysis of echocardiograms in a large heterogeneous cohort of patients with friedreich ataxia","volume":"109","author":"S. R. Regner","year":"2012","journal-title":"Am J Cardiol"},{"key":"pone.0246633.ref026","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ane.12337","article-title":"Open-label pilot study of interferon gamma-1b in Friedreich ataxia","volume":"132","author":"L. Seyer","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"pone.0246633.ref027","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ana.24260","article-title":"Epigenetic therapy for Friedreich ataxia","volume":"76","author":"E. Soragni","year":"2014","journal-title":"Ann Neurol"},{"key":"pone.0246633.ref028","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nm.3510","article-title":"Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich\u2019s ataxia","volume":"20","author":"M. Perdomini","year":"2014","journal-title":"Nature medicine"},{"key":"pone.0246633.ref029","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S1474-4422(16)30287-3","article-title":"Progression characteristics of the European Friedreich\u2019s Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study","volume":"15","author":"K. Reetz","year":"2016","journal-title":"Lancet Neurol"},{"key":"pone.0246633.ref030","doi-asserted-by":"crossref","first-page":"e0116396","DOI":"10.1371\/journal.pone.0116396","article-title":"The pathogenesis of cardiomyopathy in Friedreich ataxia","volume":"10","author":"A. H. Koeppen","year":"2015","journal-title":"PLoS One"},{"key":"pone.0246633.ref031","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/84818","article-title":"Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits","volume":"27","author":"H. Puccio","year":"2001","journal-title":"Nature genetics"},{"key":"pone.0246633.ref032","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/acn3.439","article-title":"Impact of diabetes in the Friedreich ataxia clinical outcome measures study","volume":"4","author":"A. McCormick","year":"2017","journal-title":"Annals of clinical and translational neurology"},{"key":"pone.0246633.ref033","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.tcb.2017.02.006","article-title":"Mitochondrial Function and Cell Size: An Allometric Relationship","volume":"27","author":"T. P. Miettinen","year":"2017","journal-title":"Trends in cell biology"},{"key":"pone.0246633.ref034","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.amjcard.2016.04.024","article-title":"Abundance and Significance of Iron, Zinc, Copper, and Calcium in the Hearts of Patients With Friedreich Ataxia","volume":"118","author":"P. C. Kruger","year":"2016","journal-title":"Am J Cardiol"},{"key":"pone.0246633.ref035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10554-016-0937-6","article-title":"Myocardial tissue remodeling after orthotopic heart transplantation: a pilot cardiac magnetic resonance study","volume":"34","author":"O. R. Coelho-Filho","year":"2018","journal-title":"The international journal of cardiovascular imaging"},{"key":"pone.0246633.ref036","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jcmg.2018.05.012","article-title":"Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease","volume":"11","author":"T. Ferreira de Souza","year":"2018","journal-title":"JACC. Cardiovascular imaging"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T10:37:02Z","timestamp":1671705422000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246633"}},"subtitle":[],"editor":[{"given":"John Lynn","family":"Jefferies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0246633","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]}}}